Related Experiment Video

Updated: Jun 7, 2026

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment
08:49

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

Triiodothyronine and brain natriuretic peptide: similar long-term prognostic values for chronic heart failure

Guliz Kozdag1, Gokhan Ertas, Teoman Kilic

  • 1Department of Cardiology, Medical Faculty, Kocaeli University, 41380 Kocaeli, Turkey. drgokhanertas@yahoo.com.tr

Texas Heart Institute Journal
|October 28, 2010
PubMed

Insights

Low free triiodothyronine and high brain natriuretic peptide levels are similar predictors of death in chronic heart failure. Combining these biomarkers may improve risk assessment for heart failure patients.

Area of Science:

  • Cardiology
  • Endocrinology
  • Biomarker Research

Background:

  • Chronic heart failure (CHF) patients exhibit independent predictors of mortality: low free triiodothyronine (FT3) and high brain natriuretic peptide (BNP).
  • Limited comparative studies exist on the prognostic value of FT3 and BNP in CHF.

Purpose of the Study:

  • To prospectively compare the prognostic values of FT3 and BNP in patients with chronic heart failure.
  • To identify predictive cutoff values for FT3 and BNP for major cardiac events.

Main Methods:

  • Prospective study of 334 CHF patients (ischemic and nonischemic dilated cardiomyopathy).
  • Measurement of FT3 and BNP levels, with major cardiac event as the primary endpoint.
  • Statistical analysis including correlation, ROC curve analysis, and multivariate analysis.

Main Results:

  • 92 patients (28%) experienced a major cardiac event during follow-up.
  • Lower FT3 and higher BNP levels were associated with major cardiac events.
  • FT3 and BNP demonstrated similar prognostic values, with cutoff values < 2.12 pg/mL for FT3 and > 686 pg/mL for BNP.
  • Multivariate analysis identified age, FT3, and BNP as independent predictors of major cardiac events.

Conclusions:

  • FT3 and BNP possess comparable prognostic capabilities for long-term outcomes in CHF.
  • Combining FT3 and BNP may enhance risk stratification for heart failure patients.

Keywords:
Biological markers/bloodcardiomyopathy, dilated/bloodeuthyroid sick syndromesheart failure/complications/chronic/pathologyhypothalamo-hypophyseal system/metabolismmultivariate analysisnatriuretic peptide, brain/bloodprognosissurvival ratetriiodothyronine/blood/deficiency

More Related Videos

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure04:20

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure

Published on: October 1, 2019

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...